What it's for (Indications)
- Dydrogesterone is an orally active progestogen indicated for a range of conditions stemming from endogenous progesterone deficiency.
- Its primary therapeutic applications include the treatment of dysfunctional uterine bleeding, which encompasses scenarios like irregular menstrual cycles and prevention of excessive blood loss.
- It is also utilized in the management of endometriosis, a chronic condition characterized by endometrial tissue growth outside the uterus, by inducing decidualization and atrophy of ectopic endometrial implants.
- Furthermore, dydrogesterone is prescribed for dysmenorrhea (painful menstruation) and secondary amenorrhea (absence of menstruation), typically in conjunction with an estrogen, to induce cyclical withdrawal bleeding.
- A crucial indication is in reproductive medicine, specifically for the treatment of threatened and recurrent miscarriage, where its role is to support pregnancy by supplementing insufficient progesterone levels.
- It also plays a vital role in luteal phase support during assisted reproductive technologies (ART) to enhance implantation and pregnancy rates.
- In hormone replacement therapy (HRT), it is combined with estrogen to protect the endometrium from estrogen-induced hyperplasia and carcinoma in women with an intact uterus.
- Each of these indications requires a precise diagnostic assessment and individual therapeutic regimen.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of dydrogesterone is highly individualized and contingent upon the specific indication, patient's response, and medical history, and must always be determined by a qualified healthcare professional. For instance, in cases of dysfunctional uterine bleeding, a common regimen might involve 10 or 20 mg daily for a specified period, often from day 11 to day 25 of the menstrual cycle, to induce regular bleeding or arrest excessive flow. For endometriosis, dosages typically range from 10 mg two to three times daily, usually from day 5 to day 25 of the cycle, aimed at suppressing endometrial growth. In the context of dysmenorrhea, 10 mg once or twice daily from day 5 to day 25 is often prescribed. For luteal phase support in assisted reproductive technologies (ART), a dose of 10 mg orally three times daily is frequently initiated from the day of oocyte retrieval, continuing until approximately the 10th to 12th week of gestation if pregnancy is confirmed. In threatened miscarriage, an initial dose of 40 mg may be given, followed by 10 mg every eight hours until symptoms subside, whereas for recurrent miscarriage, 10 mg twice daily is commonly administered from conception until the 20th week of pregnancy. For hormone replacement therapy (HRT) in combination with estrogen, dydrogesterone 10 mg daily for 14 sequential days of a 28-day cycle, or a continuous regimen, is typically employed to provide endometrial protection. Patients should strictly adhere to their prescribed dosage and never self-adjust the regimen. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated, dydrogesterone can be associated with a spectrum of side effects, ranging from mild and transient to more serious.
- Common adverse reactions reported include headaches and migraines, gastrointestinal disturbances such as nausea, vomiting, and abdominal pain.
- Breast tenderness or pain is also a frequently observed side effect.
- Menstrual irregularities, including spotting, breakthrough bleeding, or changes in menstrual flow and timing, can occur, particularly at the beginning of treatment.
- Weight gain and mood changes, including depressive symptoms, have also been noted.
- Less common but potentially serious side effects include hypersensitivity reactions manifest as skin rash, pruritus (itching), or urticaria (hives).
- Liver function abnormalities, sometimes accompanied by jaundice or asthenia, have been reported and necessitate prompt medical attention.
- Though dydrogesterone is generally considered to have a lower thrombogenic risk compared to some other progestogens, the potential for venous thromboembolic events (VTE), such as deep vein thrombosis or pulmonary embolism, exists, especially when used in combined hormone replacement therapy regimens.
- Dizziness and edema (fluid retention) are also possible.
- Patients should be informed about these potential effects and advised to contact their healthcare provider if any concerning symptoms develop.
Serious Warnings
- Black Box Warning: **Serious Warnings** It is important to note that dydrogesterone, as a standalone medication, does not carry a formal FDA Black Box Warning. However, healthcare professionals and patients should be aware of several serious risks, particularly when dydrogesterone is used in combination with estrogens as part of hormone replacement therapy (HRT), or in individuals with pre-existing conditions. * **Venous Thromboembolism (VTE) Risk:** Although dydrogesterone is considered to have a more favorable safety profile regarding VTE compared to certain synthetic progestins, the risk of developing deep vein thrombosis (DVT) or pulmonary embolism (PE) is still present. This risk is notably increased when dydrogesterone is used in combination with estrogens in HRT, especially during the first year of therapy, and in patients with known risk factors such as severe obesity, prolonged immobilization, personal or family history of VTE, or recent major surgery. Treatment should be discontinued immediately if any symptoms of a thromboembolic event occur. * **Breast Cancer Risk:** In women using combined estrogen-progestogen HRT for more than 5 years, an increased risk of breast cancer has been observed. This risk is a class effect for combined HRT, and while specific data for dydrogesterone-containing HRT are evolving, the general principle applies. Regular breast examinations and mammography are essential for all women receiving HRT. * **Endometrial Cancer Risk:** For women with an intact uterus, unopposed estrogen therapy increases the risk of endometrial hyperplasia and carcinoma. The addition of a progestogen like dydrogesterone is crucial to counteract this risk by inducing a secretory transformation of the endometrium. Any persistent or recurrent abnormal uterine bleeding during therapy must be thoroughly investigated to rule out endometrial malignancy. * **Hepatic Impairment:** Dydrogesterone is metabolized in the liver. Patients with a history of severe liver disease or current significant liver dysfunction should be monitored carefully. Jaundice or other symptoms of hepatic impairment may necessitate discontinuation of therapy. * **Cardiovascular Events:** The Women's Health Initiative (WHI) study indicated an increased risk of stroke and myocardial infarction in women using combined estrogen-progestin HRT. While data specifically for dydrogesterone are limited, a cautious approach is warranted for patients with pre-existing cardiovascular disease or significant risk factors.
- Dydrogesterone, despite its generally favorable safety profile, warrants specific warnings, especially when considering its use in different patient populations and therapeutic contexts.
- Healthcare professionals should exercise caution in patients with a history of or predisposition to venous thromboembolism (VTE).
- While the thrombogenic risk of dydrogesterone is considered lower than that of certain synthetic progestins, particular vigilance is required in patients with risk factors like severe obesity, prolonged immobilization, recent major surgery, or a personal or family history of VTE.
- The use of dydrogesterone in combination with estrogen as part of hormone replacement therapy (HRT) has been associated with an increased risk of VTE, stroke, myocardial infarction, and breast cancer, consistent with findings from large-scale studies such as the Women's Health Initiative (WHI) for combined HRT.
- Therefore, a thorough risk-benefit assessment is imperative.
- Patients with impaired hepatic function should be closely monitored, as dydrogesterone is metabolized in the liver, and dosage adjustments or discontinuation may be necessary if liver function deteriorates.
- A history of depression necessitates careful observation, as symptoms may recur or worsen during treatment.
- Patients experiencing new onset of migraine-type headaches, visual disturbances, or symptoms indicative of thromboembolic events must discontinue therapy and seek immediate medical evaluation.
- Regular breast examinations and mammograms are recommended for women on HRT.
- Dydrogesterone is not indicated for contraception.
How it Works (Mechanism of Action)
Dydrogesterone is a synthetic progestogen that is stereoisomerically similar to natural progesterone but possesses distinct pharmacological properties. Unlike many synthetic progestins, dydrogesterone is a retroprogesterone, meaning the hydrogen at position 9 and the methyl group at position 10 are in an inverted configuration compared to natural progesterone. This unique structure contributes to its high oral bioavailability and specific activity. Dydrogesterone acts directly on the uterus, inducing a full secretory transformation of the estrogen-primed endometrium. This action is crucial in conditions of progesterone deficiency, as it stabilizes the endometrial lining, preventing excessive proliferation induced by unopposed estrogen and promoting its differentiation, which is essential for successful embryo implantation and maintenance of pregnancy. Dydrogesterone exhibits high affinity for the progesterone receptor, but, importantly, it lacks estrogenic, androgenic, anabolic, or corticosteroid activity, which differentiates its side effect profile from that of other synthetic progestins. It does not inhibit ovulation at therapeutic doses typically used for luteal support or menstrual cycle regulation, thus preserving the natural ovulatory cycle in many cases. Its primary mechanism revolves around restoring the physiological progesterone balance, thereby supporting endometrial health and pregnancy outcomes where progesterone insufficiency is a contributing factor.